The Prefilled Auto Injectors Market is poised for robust expansion driven by escalating incidence of chronic conditions, heightened demand for self-administration therapeutics, and intensifying focus ...

Stevanato Group (NYSE:STVN) executives said the company closed fiscal 2025 with “solid” results and entered 2026 with positive momentum, driven by continued strength in its Biopharmaceutical and Diagn ...

Automotive and industrial parts distributor Genuine Parts will separate into two independent companies, it said on Tuesday, months after a deal with activist investor Elliott Investment Management.

Avonex is a prescription drug that treats relapsing forms of multiple sclerosis (MS) in adults, such as relapsing-remitting MS, active secondary progressive MS, and clinically isolated syndrome.

It took decades to develop the first treatments to address the root causes of Alzheimer’s disease, and when they first reached patients, they weren’t exactly convenient to take. Patients have to visit ...

But, despite this setback, we've got everything about the Steam machine you need to know, from its specs, whether it comes with a Steam Controller and the latest news. And while a delay is ...

CSL Behring's Andembry can be used to prevent recurrent attacks of hereditary angioedema (HAE) by the NHS, according to finalised guidance from reimbursement authority NICE. The just-published ...

・It is unclear what the company intends to charge for the vials, the report said. ・Unlike Novo, Eli Lilly and Company already sells its obesity drug Zepbound in both injector pen and vial formats.

CSL has FDA approval for its new drug to prevent hereditary angioedema (HAE) attacks, Andembry, offering a new, first-in-class option for patients with the rare genetic disorder. Factor XIIa inhibitor ...

Eli Lilly has launched a new multi-dose version of its popular obesity drug Zepbound, giving patients a full month's worth of injections in a single pen device. The new KwikPen, which holds four ...

Welcome to Camurus' Q4 Report 2025. [Operator Instructions] Now I'll hand the conference over to CEO, Fred Tiberg. Please go ahead. Thank you, Einar, and hello, everyone. Welcome to our fourth quarter ...

Pfizer Inc. announced that the US Food and Drug Administration (FDA) has accepted and granted Priority Review for the company’s supplemental Biologics License Application (sBLA) for Hympavzi ...